Panax pharma Pharmaceutical Company is an Egyptian “closed” Joint-Stock Company established in 2007 under the laws of the Arab Republic of Egypt, Panax pharma main business includes development, manufacturing, marketing, distribution, and export of a wide range of human pharmaceutical and animal health products.
Panax pharma maintains a robust product portfolio that offers a wide range of much needed pharmaceutical therapies and treatments. With a strong product pipeline strategy, Panax pharma currently has more than 130 new product at various stages of registration that were carefully selected in order to address many un-met therapeutic needs, such as high prevalence diseases and other diseases of high national interest Panax pharma product portfolio and product pipeline will endure further expansions for many years to come and will continue to play a major role in driving growth and in increasing shareholders’ value.
As one of the leading drug makers in Egypt, Panax pharma conducts its commercial operations through five commercial branches spread out through the country and currently operates a large, modern plant in “El-Obour City”, a suburb near Cairo. Panax pharma ’s state-of-the-art factory – designed by an American architectural firm – is considered to be one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East.
Panax pharma ’s growth and expansion is due to the vision, determination and market know-how of its leadership, management and staff. Led by Dr. Mohamed selim a 20 + years of experience in multinational and local pharmaceutical organizations. selim is member of European association for medical and pharmacist ” for innovators, multinationals, regulators and the surrounding communities. With the Company’s leadership team well vested knowledge of the Middle Eastern and African markets, hands on knowledge of all aspects of the pharmaceutical business and Panax pharma well-established infrastructure; Panax pharma certainly speaks the language of innovators and of multinationals, and therefore, has earned its credibility among local and regional regulators as well as all stakeholders.See more